Alnylam Defends Heart Drugs After Wainua Trial Failure — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca on Friday detailed the failed trial of its drug Wainua in the heart condition ATTR-CM.
- Some analysts interpreted the miss as a broad signal that RNA silencers offer no added benefit when patients are already on stabilizers, and suggested stabilizers might be superior.
- Alnylam is mounting a defense of its silencer medicines in response to that analyst framing.
- The defense carries ramifications for Alnylam's marketed drug Amvuttra, already on the market.
- It also carries ramifications for Alnylam's next-generation treatment nucresiran, which the company is developing.
- The dispute pits silencers — the drug class Alnylam sells and AstraZeneca was testing with Wainua — against stabilizers, the established alternative therapy.
Why it matters: AstraZeneca's Wainua failure has become a proxy battle for whether the entire RNA-silencer drug class adds clinical value beyond existing stabilizer therapy in ATTR-CM. Alnylam's defense aims to protect both its commercial franchise in Amvuttra and the commercial thesis for its next-generation candidate nucresiran against an analyst narrative that could weigh on the company's market position and pipeline valuation.
Ask SkimNews
